Pirtobrutinib for the Treatment of B-Cell Malignancies: Recent Developments
Bruton tyrosine kinase (BTK) plays a vital role in B-cell functions, including differentiation, proliferation and survival, and has emerged as a critical therapeutic target of several generations of kinase inhibitors. Approved covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2024-12-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/HBT.OH.2024.22.162 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Bruton tyrosine kinase (BTK) plays a vital role in B-cell functions, including differentiation, proliferation and survival, and has emerged as a critical therapeutic target of several generations of kinase inhibitors. Approved covalent BTK inhibitors such as ibrutinib, acalabrutinib and zanubrutinib have demonstrated remarkable antitumor activity, resulting in regulatory approvals for treating various hematological malignancies. However, these drugs are associated with off-target toxicities and the development of resistance. To address these challenges, newer noncovalent BTK inhibitors, such as pirtobrutinib, have been developed. Pirtobrutinib has shown promising efficacy in many B-cell malignancies, including mantle cell lymphoma, chronic lymphocytic leukemia, Waldenström macroglobulinemia and marginal zone lymphoma. This article summarizes recent updates from clinical studies evaluating pirtobrutinib in patients with relapsed/refractory B-cell malignancies.
PEER REVIEWED ARTICLE
**Peer reviewers:**
Dr Ilaria Romano, Institute of Oncology Research and Cantonal Hospital Bellinzona, Bellinzona, Switzerland
Dr Nadia Djerbi, University Hospital Zurich, Zurich, Switzerland
Dr Nathan Cantoni, Cantonal Hospital Aarau, Aarau
Received on September 20, 2024; accepted after peer review on December 06, 2024; published online on December 16, 2024. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |